Quigley Jill M. — SEC insider filings
SEC reporting owner CIK 1799780. 22 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2021-01-15 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 7 filings — 104,118 shares, $1,490,991 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 31.
- Largest priced transaction: sale of 16,298 shares @ $30.10 ($490,570) in Passage BIO, Inc., filed 2021-01-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Terns Pharmaceuticals, Inc. (TERN) | Director | 15 | — | 8 legs · 86,520 sh · $961,410 | 24 |
| Passage BIO, Inc. (PASG) | Chief Operating Officer | 4 | — | 2 legs · 17,598 sh · $529,581 | 4 |
| Chemomab Therapeutics Ltd. (CMMB) | Director | 1 | — | — | 2 |
| FILANA THERAPEUTICS, INC. (FLNA) | Director | 2 | — | — | 1 |
Insider filings — Quigley Jill M.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 3 | FILANA THERAPEUTICS, INC. (FLNA) | Holdings only — no transactions reported | EDGAR |
| 2026-11-12 | 4 | FILANA THERAPEUTICS, INC. (FLNA) | Grant/award (A): 53,000 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 10,657 (derivative) · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 3,955 (derivative) · Disposition to issuer (D): 22,000 (derivative) · Disposition to issuer (D): 32,000 (derivative) · +1 more | EDGAR |
| 2026-02-02 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 1,697 (derivative) @ $0 | EDGAR |
| 2025-11-05 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Option exercise (M): 24,520 @ $9.24 · Sale (S): 24,520 @ $18 · Option exercise (M): 24,520 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 10,657 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Sale (S): 6,240 @ $5.72 · Sale (S): 8,760 @ $5.79 | EDGAR |
| 2024-09-11 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Option exercise (M): 17,235 @ $1.82 · Sale (S): 17,235 @ $10 · Option exercise (M): 17,235 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Sale (S): 6,143 @ $7.68 · Sale (S): 8,857 @ $7.50 | EDGAR |
| 2024-07-17 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Option exercise (M): 14,365 @ $1.82 · Sale (S): 14,365 @ $10.00 · Option exercise (M): 400 @ $1.82 · Sale (S): 400 @ $10 · Option exercise (M): 14,365 (derivative) @ $0 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 15,000 @ $0 | EDGAR |
| 2023-11-17 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 15,000 @ $0 | EDGAR |
| 2023-06-20 | 4 | Chemomab Therapeutics Ltd. (CMMB) | Grant/award (A): 6,857 (derivative) @ $0 · Grant/award (A): 13,640 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2021-12-10 | 4 | Passage BIO, Inc. (PASG) | Option exercise (M): 71,975 @ $0.23 · Option exercise (M): 11,193 (derivative) @ $0 · Option exercise (M): 60,782 (derivative) @ $0 | EDGAR |
| 2021-09-30 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2021-02-18 | 4 | Passage BIO, Inc. (PASG) | Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2021-01-22 | 4 | Passage BIO, Inc. (PASG) | Sale (S): 1,300 @ $30.01 | EDGAR |
| 2021-01-15 | 4 | Passage BIO, Inc. (PASG) | Sale (S): 16,298 @ $30.10 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1799780 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs